breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Æxlishemjandi lyf - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
zarator filmuhúðuð tafla 80 mg
upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 80 mg
zarator filmuhúðuð tafla 40 mg
upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 40 mg
zarator filmuhúðuð tafla 20 mg
upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 20 mg
zarator filmuhúðuð tafla 10 mg
upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 10 mg
cernevit stungulyfsstofn, lausn
baxter medical ab* - vítamín a (palmítat); colecalciferolum inn; vítamín e (tocoferolum nfn); acidum ascorbicum inn; thiaminum cocarboxylase tetrahýdrat; riboflavinum natríumfosfat díhýdrat; pyridoxinum hýdróklóríð; cyanocobalaminum inn; acidum folicum inn; dexpanthenolum inn; biotinum inn; nicotinamidum inn - stungulyfsstofn, lausn
trileptal mixtúra, dreifa 60 mg/ml
novartis healthcare a/s - oxcarbazepinum inn - mixtúra, dreifa - 60 mg/ml
malaseb vet. hársápa 2 % w/v
dechra veterinary products a/s* - chlorhexidinum díglúkónat; miconazolum nítrat - hársápa - 2 % w/v
imurel filmuhúðuð tafla 25 mg
aspen pharma trading limited - azathioprinum inn - filmuhúðuð tafla - 25 mg
imurel filmuhúðuð tafla 50 mg
aspen pharma trading limited - azathioprinum inn - filmuhúðuð tafla - 50 mg